Literature DB >> 31310900

Elevated Mortalin correlates with poor outcome in hepatocellular carcinoma.

Wei Cheng1, Bin Zhang1, Mulager Zikeliyar1, Junqiao Wang1, Huiling Jian1, Kexiong Wu1, Yizhi Zhang1, Jinhui Ding2.   

Abstract

Although several lines of evidence existed suggesting that Mortalin was linked with survival in malignant tumors; it has been barely described regarding the prognostic involvement of its expression in hepatocellular carcinoma (HCC). Herein, to understand the prognostic meaning of Mortalin expression, Immunohistochemistry was undertaken to observe the immunohistochemical characteristics of Mortalin on HCC tissue microarray consisting of 90 cases of HCC and its paired normal control dots, followed by detailed statistical analysis with the accompanying clinicopathological variables available, including gender, age, tumor size, differentiation, cirrhosis, vascular invasion, clinical stage, T classification and intrahepatic metastases. Meanwhile, Kaplan-Meier survival curve was plotted to analyze the prognostic difference for patients with high and low expression of Mortalin. It was exhibited that Mortalin was over-expressed in HCC tissues relative to paired normal control and elevated Mortalin significantly correlated with vascular invasion, clinical stage and intrahepatic metastasis. Kaplan-Meier survival analysis revealed that Mortalin was remarkably associated with overall survival and disease-free survival. Multivariate Cox regression analysis showed that expression of Mortalin was an independent prognostic factor in HCC. Collectively, the data we provided here support the prognostic prediction value of Mortalin in HCC.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); Metastasis; Mortalin; Prognostic

Mesh:

Substances:

Year:  2019        PMID: 31310900     DOI: 10.1016/j.anndiagpath.2019.06.011

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  6 in total

1.  Targeting Colon Cancer Cells with Enzyme-Triggered Casein-Gated Release of Cargo from Mesoporous Silica-Based Nanoparticles.

Authors:  Nisitha Wijewantha; Morgan M Eikanger; Ryan M Antony; Rashaun A Potts; Khosrow Rezvani; Grigoriy Sereda
Journal:  Bioconjug Chem       Date:  2021-10-21       Impact factor: 4.774

Review 2.  Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets.

Authors:  Rajani Rai; Amy L Kennedy; Zitha Redempta Isingizwe; Pouya Javadian; Doris Mangiaracina Benbrook
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 3.  Insight into the mitochondrial unfolded protein response and cancer: opportunities and challenges.

Authors:  Ge Wang; Yumei Fan; Pengxiu Cao; Ke Tan
Journal:  Cell Biosci       Date:  2022-02-18       Impact factor: 7.133

4.  Pre-clinical safety and therapeutic efficacy of a plant-based alkaloid in a human colon cancer xenograft model.

Authors:  Jessica L Freeling; Jamie L Scholl; Morgan Eikanger; Cole Knoblich; Rashaun A Potts; David J Anderson; Joseph E Rower; Mohammad Hadi Farjoo; Haotian Zhao; Angela Pillatzki; Khosrow Rezvani
Journal:  Cell Death Discov       Date:  2022-03-28

Review 5.  Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease.

Authors:  Baptiste Texier; Morgane Prime; Djamaa Atamena; Pascale Belenguer; Marion Szelechowski
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

6.  Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.

Authors:  Vishal Chandra; Rajani Rai; Doris Mangiaracina Benbrook
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.